Used in pharmaceutical research as a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), this compound shows promise in the development of treatments for autoimmune diseases and certain B-cell malignancies. It modulates B-cell receptor signaling, leading to reduced activation, proliferation, and survival of malignant or autoreactive B cells. Due to its high selectivity and favorable pharmacokinetic profile, it serves as a lead candidate in the design of oral therapies for conditions such as rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. Its nitrile and pyrrolidine-containing structure enhances binding affinity and blood-brain barrier penetration, making it valuable in both peripheral and central nervous system-targeted therapies.